MedTrace Logo

Protective Effects of Edaravone Dexborneol

NCT05024526 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-09-13

No results posted yet for this study

Summary

The patients of acute ischemic stroke were divided into two groups, edaravone dexborneol treatment group and edaravone treatment group. The purpose of this study was to observe the changes of imaging and the improvement of NIHSS and mRS in different groups.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

edaravone dexborneol or edaravone

Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.

Sponsors & Collaborators

  • Lili Cao

    lead OTHER

Principal Investigators

  • Yu-Qing Fang, MD · Shandong Provincial Qianfoshan Hospital，The First Affiliated Hospital of Shandong First Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05024526 on ClinicalTrials.gov